Int. J. Sci. R. Tech., 2025 2(5)
A Multidisciplinary peer-reviewed Journal
www.ijsrtjournal.com [ISSN: 2394-7063]

Original Article

Formulation and Evalution of Clindamycin Gel

Deshmukh Ajinkya*[1], Dr. Priti Shinde[2]

[1]*Research Scholar, Department of Pharmaceutics, Delight College of Pharmacy, Koregaon Bhima, Pune, Maharashtra, India 412216.*
[2]*Assistant Professor, Department of Pharmaceutics, Delight College of Pharmacy, Koregaon Bhima, Pune, Maharashtra, India 412216*

ABSTRACT

The present study focuses on the formulation and development of a topical Clindamycin gel intended for the treatment of acne vulgaris. Clindamycin, a lincosamide antibiotic, exhibits potent antibacterial activity against Propionibacterium acnes, a key pathogen involved in acne pathogenesis. A gel formulation was selected due to its superior aesthetic appeal, ease of application, and ability to localize drug delivery at the site of infection. The gel was prepared using Carbopol 940 as the gelling agent, along with propylene glycol as a humectant and penetration enhancer. Methylparaben and propylparaben were incorporated as preservatives, while triethanolamine was used to neutralize the pH and activate the gelling property of Carbopol. The formulation was evaluated for various physicochemical parameters including pH, viscosity, spreadability, drug content, and in vitro drug release. The developed gel exhibited satisfactory physical characteristics, acceptable pH for topical application, and consistent drug content with sustained drug release. This study demonstrates the potential of a Clindamycin topical gel as an effective, stable, and patient compliant therapeutic system for the management of acne.

Keywords: Clindamycin, Acne vulgaris, Topical gel, Carbopol 940, Antibacterial, Drug formulation, In vitro release, Skin delivery

INTRODUCTION

Acne vulgaris is one of the most common dermatological disorders, affecting millions of individuals worldwide, particularly adolescents and young adults. It is a multifactorial skin disease characterized by inflammation of the pilosebaceous units, leading to the formation of comedones, papules, pustules, and in severe cases, cysts and nodules. The primary causative agent involved in acne pathogenesis is *Propionibacterium acnes*, an anaerobic Gram-positive bacterium that colonizes the sebaceous follicles. Topical therapy remains the cornerstone for treating mild to moderate acne due to its localized action, reduced systemic side effects, and improved patient compliance. Among the various topical agents, **Clindamycin**—a lincosamide antibiotic—has proven effective in suppressing *P. acnes* by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit. Formulating Clindamycin into a **topical gel** provides several advantages over other dosage forms such as creams or lotions. Gels are non-greasy, have a cooling effect upon application, and allow for better drug penetration through the skin. Moreover, they offer good spreadability, patient acceptability, and controlled drug release. The current study aims to formulate a stable and effective Clindamycin gel using **Carbopol 940** as the gelling agent, along with other excipients to enhance stability, skin penetration, and antimicrobial efficacy. The formulation is evaluated for key parameters such as pH, viscosity, drug content, spread ability, and in vitro drug release to ensure optimal therapeutic performance.

Profile of Formulation Ingredients[4]:

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



Clindamycin Phosphate

Role: Active Pharmaceutical Ingredient (API)

Function: Lincosamide antibiotic; inhibits protein synthesis in Cutibacterium acnes. Provides antimicrobial and anti-inflammatory action for acne treatment.

Concentration: Typically, 1% or 2% in the gel formulation, depending on the product.

2. Purified Water

Role

Function: Acts as the main solvent and carrier for all water-soluble ingredients. Ensures the formulation is smooth, stable, and skin compatible.

Concentration: Usually, a significant part of the formulation (often 60 80%)

3.Glycerin

Role: Humectant / Moisturizer

Function: Retains moisture on the skin and prevents dryness. Enhances skin feel and helps balance the drying effect of ethanol and carbomer.

4.Propylene Glycol

Role: Penetration Enhancer / Humectant

Function: Enhances percutaneous absorption of clindamycin. Also acts as a solvent and moisturizer, improving skin hydration.

5.Carbomer 940 Role: Gelling Agent

Function: Provides gel structure and viscosity. Ensures uniform distribution of the API and improves spread ability.

6. Triethanolamine

Role: pH Adjuster / Neutralizer

Function: Used to neutralize the acidic carbomer, forming the gel matrix. Also helps maintain formulation pH within a skin compatible range (≈5.5–6.5)

7.Methylparaben

Role: Preservative

Function: Prevents microbial growth in the formulation, enhancing product stability and safety during storage and use.

8. Ethanol

Role: Antiseptic solvent

Function: Ethanol acts as a solvent, helping to dissolve clindamycin phosphate and other ingredients to form a stable and uniform gel.

1. Clindamycin Phosphate

Role: Active Pharmaceutical Ingredient (API)

Function: Lacosamide antibiotic; inhibits protein synthesis in Cutibacterium acnes. Provides antimicrobial and anti-inflammatory action for acne treatment.

Concentration: Typically, 1% or 2% in the gel formulation, depending on the product.

2. Purified Water

Role: Solvent & Base

Function: Acts as the main solvent and carrier for all water-soluble ingredients. Ensures the formulation is smooth, stable, and skin compatible.

Concentration: Usually, a significant part of the formulation (often 60 80%).

3. Glycerine

Role: Humectant / Moisturizer

Function: Retains moisture on the skin and prevents dryness. Enhances skin feel and helps balance the drying effect of ethanol and carbomer.

4. Propylene Glycol

Role: Penetration Enhancer / Humectant

Function: Enhances percutaneous absorption of clindamycin. Also acts as a solvent and moisturizer, improving skin hydration.

5. Carbomer 940

Role: Gelling Agent

Function: Provides gel structure and viscosity. Ensures uniform distribution of the API and improves spread ability.

6. Triethanolamine

Role: pH Adjuster / Neutralizer

Function: Used to neutralize the acidic carbomer, forming the gel matrix. Also helps maintain formulation pH within a skin compatible range (≈5.5–6.5).

7. Methylparaben

Role: Preservative

Function: Prevents microbial growth in the formulation, enhancing product stability and safety during storage and use.

8. Ethanol

Role: Antiseptic Solvent

Function: Acts as a solvent, helping to dissolve clindamycin phosphate and other ingredients to form a stable and uniform gel.

EXPERIMENTAL WORK:

Carbopol 940 was used as the gelling agent, dispersed in purified water and allowed to swell for several hours to form the gel base.

Clindamycin phosphate was dissolved in water and incorporated into the gel base along with preservatives (methylparaben and propylparaben) dissolved in propylene glycol. The gel was neutralized using triethanolamine to adjust the pH to 5.5–6.0, which activated gel formation. The final gel was evaluated for pH, viscosity, spreadability, drug content, and in vitro drug release using standard methods. **Stability studies** were conducted at different storage conditions to assess the formulation's physical and chemical stability over time.

METHODOLOGY:

The chemical and reagents apply from Delight college of pharmacy Koregaon Bhima, Pune. Maharashtra, India 412216.

S. No.	Ingredients	Quantity (per 30 g)	Purpose
1	Clindamycin Phosphate	0.3 g	Active pharmaceutical ingredient (API); anti-acne
2	Glycerin	3g (Typically 10% of the total gel weight).	Humectant
3	Propylene Glycol	2gm	Solvent; penetration enhancer
4	Carbomer (e.g., Carbomer 934)	0.6g	Thickener to provide the gel's consistency.
5	Triethanolamine	0.3g	pH adjuster (neutralizes the carbomer and thickens the gel).

6	Methylparaben	0.15g (Typically 0.5% of the gel weight).	Preservative to prevent microbial growth.
7	Ethanol	2.4g	Solvent and enhances the gel's penetration on the skin.
8	Purified Water	21.95g	Solvent to dissolve and mix all ingredients.

1. Preparation of Active Ingredient Solution:

- Dissolve Clindamycin phosphate (0.3 g) in purified water to create a homogeneous solution. This serves as the active pharmaceutical ingredient for acne treatment.

2. Gel Base Preparation:

- In a separate container, mix Carbomer 934 (0.6 g) with purified water (21.95 g) while stirring to create a gel base. Allow the Carbomer to hydrate and thicken the mixture, forming the gel's consistency.

3. Addition of Humectants and Solvents:

- Add Glycerin (3 g) as a humectant to retain moisture in the skin, followed by Propylene glycol (2 g) to serve as a solvent and penetration enhancer. Additionally, include Ethanol (2.4 g) to further enhance the gel's penetration properties.

4. pH Adjustment and Neutralization:

- Gradually add **Triethanolamine (0.3 g)** to the gel mixture while stirring to adjust the pH to the desired range (typically 5.5–6.0). This neutralizes the **Carbomer**, activating its gelling properties and thickening the formulation.

5. Preservation and Final Mixing:

- Add **Methylparaben (0.15 g)** to the gel as a preservative to prevent microbial growth. Mix the entire formulation thoroughly to ensure uniform consistency and stability before packaging the gel into suitable containers.

OBSERVATION:

1. Colour: The appearance of the gel should be aesthetically acceptable. The colour may vary from slightly cloudy to clear depending on the presence and concentration of ethanol in the formulation.

Procedure: Visually inspect a small amount of gel against a white background under natural or white light to observe its clarity and colour.

2. Odor: The gel should possess a mild and pleasant odor. If ethanol is used, an alcohol like Odor may be present, which is acceptable.

Procedure: Take a small quantity of the gel on a spatula and gently smell it to evaluate the presence of any characteristic or unpleasant odor.

3. Consistency: A good gel should have a uniform and semi solid consistency that is easy to apply and spread over the skin surface.

Procedure: Check the gel manually by pressing a small quantity between the fingers to assess its smoothness, uniformity, and feel.

4. PH: The pH of the gel should be compatible with the skin (between 6.5 to 7.0) to avoid irritation upon application.

Figure 1: PH Meter

Procedure:

1. Dissolve 1g of the gel in 10 ml of distilled water.
2. Measure the pH using a calibrated digital pH meter.

Theory: This test ensures how easily the gel spreads on the skin, which affects patient compliance and drug delivery.

5. Spreadability



Spread ability (gm./s) = M×L/T

Where:
M = Weight in grams
L = Length the slide moved (in cm)
T = Time in seconds

Procedure:

1. Place a small quantity of gel between two glass slides.
2.Apply a weight (usually 500g) on the top slide for 1 minute.
3. Measure the diameter of the spread gel area or note the time taken for the top slide to slip off.

6. Drug Solubility: The active ingredient (Diclofenac Sodium) must be fully dissolved in the gel base to ensure uniform distribution and efficacy.

Procedure:

1. Visually inspect for any undissolved particles.

Optionally, analyse using UV spectrophotometry to confirm drug solubility in the formulation.

7. Viscosity: Viscosity determines the flow properties and stability of the gel. An ideal gel should have adequate viscosity for proper application and retention.

Figure 3: Brookfield Viscometer

Procedure:

1. **Prepare the Sample**:

- Ensure the **clindamycin gel** is homogenous and at room temperature (25°C) or body temperature (37°C).

2. **Setup**:

- Attach the appropriate spindle (e.g., **RV Spindle 64**) to the **Brookfield Viscometer**.
- Place the gel in a **250 mL beaker** (about 100 200 mL) and immerse the spindle, ensuring it doesn't touch the sides or bottom.

3. **Set Speed**:

- Set the viscometer to **12 RPM** (or 10/50 RPM for different shear rates).

4. **Measure Viscosity**:

- Allow the spindle to rotate for **30 60 seconds**.
- Record the **viscosity in cP** (centipoise) from the digital display.

5. **Repeat (Optional)**:

- Measure viscosity at **different speeds** (10, 20, 50 RPM) to assess shear thinning behavior.

6. **Clean Up**: Clean the spindle and container thoroughly after use.

8. Simple Diffusion Test for Diclofenac Gel

MATERIALS:

1. clindamycin gel
2. Franz diffusion cell (or small glass setup)
3.Dialysis membrane or cling film
4. Warm water (37°C)
5. Phosphate buffered saline (PBS)

Figure 4: Franz Cell Diffusion Apparatus

Steps:

1. Prepare Membrane: Soak membrane in warm PBS for 10 minutes.

2. Set Up Cell: Place membrane between two compartments:

1. Top (Donor): Apply 1g diclofenac gel
2. Bottom (Receptor): Fill with PBS

3. Keep Warm & Stir: Keep setup at 37°C and stir the PBS.

4. Sample at Times: Every 30 mins, take a few drops from PBS below.

RESULT:

The Clindamycin gel prepared for topical application exhibited a clear, smooth, and homogeneous appearance, with no visible separation or clumping, indicating proper formulation. The pH of the gel was found to be 5.7, which is within the optimal range of 5.5–6.0, ensuring skin compatibility and minimizing potential irritation. The viscosity of the gel, measured at approximately 2500 cps, demonstrated the gel's ideal consistency—neither too thick nor too runny—making it easy to apply with good spreadability. The spreadability of the gel was assessed and found to be 4.2 cm, indicating that the gel can cover a large surface area with minimal effort, which is desirable for topical applications. The drug content uniformity test revealed that Clindamycin was uniformly distributed in the gel, with the drug content being 98% of the labeled claim, ensuring accurate dosing with each application. In vitro drug release studies, conducted using a Franz diffusion cell, showed a sustained release of Clindamycin over a 12-hour period, with approximately 75% of the drug released within the first 6 hours. This sustained release suggests that the gel provides prolonged therapeutic effects, suitable for acne treatment. Finally, the gel formulation underwent stability studies under accelerated conditions (40°C/75% RH) for 3 months. No significant changes were observed in the appearance, pH, viscosity, or drug content, indicating that the gel is stable and retains its effectiveness over time.

SUMMARY AND CONCLUSION:

The Clindamycin gel was successfully formulated using Clindamycin phosphate as the active pharmaceutical ingredient, combined with Carbomer 934 as a thickening agent, and other excipients including Glycerin, Propylene Glycol, Triethanolamine, Methylparaben, Ethanol, and Purified Water. The gel was evaluated for its appearance, pH, viscosity, spreadability, drug content uniformity, and in vitro drug release. The gel demonstrated clear, smooth, and homogeneous characteristics, with a pH of 5.7, which is suitable for skin application. The viscosity and spreadability tests indicated that the gel had the appropriate thickness and could be easily spread over the skin. The drug content was uniform, with 98% of the labeled Clindamycin content. The in vitro drug release study revealed a sustained release profile, indicating prolonged therapeutic action over 12 hours. Stability studies confirmed that the gel remained stable without significant changes in appearance, pH, or drug content over three months under accelerated conditions.

CONCLUSION

The formulated Clindamycin gel meets the required physicochemical properties for an effective topical treatment for acne. The gel exhibits optimal pH, viscosity, and spreadability, ensuring ease of application and skin compatibility. The sustained release of Clindamycin indicates that the gel can provide prolonged therapeutic effects, making it suitable for acne management. The uniform distribution of the active ingredient and the results of stability studies suggest that the gel is both effective and stable over time. Thus, the formulation can be considered a promising candidate for further development and potential clinical use in acne treatment.

REFERENCE

1. Sourabh, K., et al. (2020). "Formulation and evaluation of topical Clindamycin gel for acne treatment." Journal of Pharmaceutical Sciences, 104(9), 3018 3025.
2. Chrysafides, L., & Williams, D. (2019). "Topical antibiotic therapy in acne vulgaris: A review of the literature." American Journal of Clinical Dermatology, 21(5), 573 585.

3. Del Rosso, J. Q., & Kircik, L. H. (2015). "Clindamycin phosphate 1.2% topical gel: A new treatment option for acne vulgaris." Journal of Clinical and Aesthetic Dermatology, 8(11), 22 30.
4. Trivedi, S., et al. (2021). "Development and characterization of Clindamycin phosphate gel for acne vulgaris." International Journal of Drug Development and Research, 13(4), 82 91.
5. Tariq, M. A., et al. (2017). "Formulation and evaluation of Clindamycin gel for acne vulgaris." Research Journal of Pharmaceutical, Biological and Chemical Sciences, 8(3), 1469 1476.
6. Ravichandran, S., & Palanisamy, P. (2016). "Development of Clindamycin gel for topical application: Preparation and evaluation." Asian Journal of Pharmaceutics, 10(4), 264 268.
7. Vaughan, M. E., et al. (2017). "Topical antibiotics in dermatology: Review and management guidelines." Dermatologic Clinics, 35(2), 227 240.
8. Karami, Z., et al. (2020). "Pharmaceutical aspects of Clindamycin in topical dosage forms." International Journal of Pharmaceutics, 578, 119 124.
9. Henderson, M., et al. (2019). "The role of Clindamycin in the treatment of acne vulgaris: A systematic review." Journal of the European Academy of Dermatology and Venereology, 33(10), 1863 1870.
10. Bhasin, S., et al. (2021). "Formulation and evaluation of Clindamycin phosphate topical gel for acne vulgaris." International Journal of Pharmaceutical Sciences and Research, 12(6), 2284 2290.
11. Sharma, R., et al. (2019). "Topical Clindamycin gel formulation for the management of acne vulgaris." American Journal of Dermatological Research, 35(4), 507 511.
12. Pande, N. S., & Saha, S. K. (2018). "Clindamycin gel for acne treatment: Formulation, evaluation, and characterization." International Journal of Research in Pharmaceutical and Biomedical Sciences, 9(1), 48 53.
13. Xu, J., et al. (2017). "In vitro release and skin permeation study of topical Clindamycin phosphate gel." Asian Journal of Pharmaceutics, 11(3), 372 377.
14. Nair, V., et al. (2018). "Pharmaceutical aspects of topical Clindamycin: A review." Pharmaceutical Technology, 42(9), 50 55.
15. Bender, L., & Green, J. (2016). "Development and characterization of topical antibiotic formulations for acne treatment." Journal of Dermatological Science, 84(1), 25 34.
16. Almeida, A. J., et al. (2020). "Evaluation of topical gel formulations: An overview on characterization techniques." Pharmaceutical Development and Technology, 25(2), 123 137.
17. Reddy, S. P., et al. (2017). "Topical gel formulations for acne treatment: A review." International Journal of Pharmaceutics, 527(1), 61 75.
18. Kumari, S., & Pandey, A. (2019). "Formulation, development, and evaluation of Clindamycin phosphate gel." International Journal of Drug Delivery Technology, 9(4), 439 445.
19. Cranston, M., & Long, S. (2016). "Pharmaceutical gels: Properties, preparation, and applications in the treatment of acne." Pharmaceutical Research, 33(2), 310 321.
20. Mohammad, S., & Chaudhary, M. (2020). "Topical drug delivery systems: The formulation and evaluation of Clindamycin gel for acne treatment." Journal of Drug Delivery Science and Technology, 59, 101889.

HOW TO CITE: Deshmukh Ajinkya*, Dr. Priti Shinde, Formulation and Evalution of Clindamycin Gel, Int. J. Sci. R. Tech., 2025, 2 (5), 665-672. https://doi.org/10.5281/zenodo.15564901